Download PDF
Clin Colon Rectal Surg 2005; 18(2): 102-108
DOI: 10.1055/s-2005-870891
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Medical Treatment of Irritable Bowel Syndrome

Jason Reina1 , James W. Smith1
  • 1Department of Gastroenterology and Hepatology, Ochsner Clinic Foundation, New Orleans, Louisiana
Further Information

Publication History

Publication Date:
24 May 2005 (online)

    Permissions and Reprints

ABSTRACT

The identification, diagnosis, and treatment of irritable bowel syndrome (IBS) have a tremendous impact on the large number of patients with this syndrome and on physicians representing a wide variety of general and specialty practices. There are well-established diagnostic criteria and algorithms for the initial evaluation of patients presenting with the symptoms of IBS. The symptoms can be targeted for therapy with a variety of pharmaceutical and nonpharmaceutical agents. Therapy should be individualized for the patient, and the cornerstone for any effective treatment strategy should be a solid patient-physician relationship. Medications released in the past several years are based on the understanding of serotonin receptors in the gut and their role in the pathogenesis of IBS.

KEYWORDS

Irritable bowel syndrome - functional gastrointestinal disease - alosetron - tegaserod

REFERENCES

  • 1 Horwitz B J, Fisher R S. The irritable bowel syndrome.  N Engl J Med. 2001;  344 1846-1850
    CrossrefPubMedGoogle Scholar
  • 2 Drossman D A, Camilleri M, Mayer E A, Whitehead W E. AGA technical review on irritable bowel syndrome.  Gastroenterology. 2002;  123 2108-2131
    CrossrefPubMedGoogle Scholar
  • 3 Whitehead W E, Burnett C K, Cook III E W, Taub E. Impact of the irritable bowel syndrome on quality of life.  Dig Dis Sci. 1996;  41 2248-2253
    PubMedGoogle Scholar
  • 4 Drossman D A, Li Z, Andruzzi E et al.. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography and health impact.  Dig Dis Sci. 1993;  38 1569-1580
    CrossrefPubMedGoogle Scholar
  • 5 Brandt L J, Bjorkman D, Fennerty M B et al.. Systematic review on the management of irritable bowel syndrome in North America.  Am J Gastroenterol. 2002;  97(suppl 11) S7-S26
    PubMedGoogle Scholar
  • 6 Manning A P, Thompson W G, Heaton K W, Morris A F. Towards positive diagnosis of the irritable bowel.  Br J Med. 1978;  2 653-654
    CrossrefPubMedGoogle Scholar
  • 7 Drossman D A, Corazziari E, Talley N J et al.. Rome II: The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology, and Treatment: A Multinational Consensus. 2nd ed. McLean, VA; Degnon Associates 2000
    Google Scholar
  • 8 Boyce P M, Koloski N A, Talley N J. Irritable bowel syndrome according to varying diagnostic criteria: are the new Rome II criteria unnecessarily restrictive for research and practice?.  Am J Gastroenterol. 2000;  95 3176-3183
    CrossrefPubMedGoogle Scholar
  • 9 Sanders D S, Carter M J, Hurlstone D P et al.. Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care.  Lancet. 2001;  358 1504-1508
    CrossrefPubMedGoogle Scholar
  • 10 Owens D M, Nelson D K, Talley N J. The irritable bowel syndrome: long-term prognosis and the physician-patient interaction.  Ann Intern Med. 1995;  122 107-112
    CrossrefPubMedGoogle Scholar
  • 11 Drossman D A. Diagnosing and treating patients with refractory functional gastrointestinal disorders.  Ann Intern Med. 1995;  123 688-697
    PubMedGoogle Scholar
  • 12 Harvey R F, Mauad E C, Brown A M. Prognosis in the irritable bowel syndrome: a 5-year prospective study.  Lancet. 1987;  1 963-965
    PubMedGoogle Scholar
  • 13 Cash B D, Schoenfeld P, Chey W D. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review.  Am J Gastroenterol. 2002;  97 2812-2819
    CrossrefPubMedGoogle Scholar
  • 14 Jailwala J, Imperiale T F, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials.  Ann Intern Med. 2000;  133 136-147
    CrossrefPubMedGoogle Scholar
  • 15 Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials.  Gut. 2001;  48 272-282
    CrossrefPubMedGoogle Scholar
  • 16 Talley N J. Pharmacologic therapy for the irritable bowel syndrome.  Am J Gastroenterol. 2003;  98 750-758
    CrossrefPubMedGoogle Scholar
  • 17 Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome.  Aliment Pharmacol Ther. 2001;  15 355-361
    CrossrefPubMedGoogle Scholar
  • 18 Page J G, Dirnberger G M. Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride).  J Clin Gastroenterol. 1981;  3 153-156
    CrossrefPubMedGoogle Scholar
  • 19 Jackson J L, O'Malley P G, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis.  Am J Med. 2000;  108 65-72
    CrossrefPubMedGoogle Scholar
  • 20 Francis C Y, Whorwell P J. Bran and irritable bowel syndrome: time for reappraisal.  Lancet. 1994;  344 39-40
    CrossrefPubMedGoogle Scholar
  • 21 Muller-Lissner S A, Fumagalli I, Bardhan K D et al.. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation.  Aliment Pharmacol Ther. 2001;  15 1655-1666
    CrossrefPubMedGoogle Scholar
  • 22 Pimentel M, Chow E J, Lin H C. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome.  Am J Gastroenterol. 2000;  95 3503-3506
    CrossrefPubMedGoogle Scholar
  • 23 Pimentel M, Chow E J, Lin H C. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study.  Am J Gastroenterol. 2003;  98 412-419
    PubMedGoogle Scholar
  • 24 Spanier J A, Howden C W, Jones M P. A systematic review of alternative therapies in the irritable bowel syndrome.  Arch Intern Med. 2003;  163 265-274
    CrossrefPubMedGoogle Scholar
  • 25 Gralnek I M, Hays R D, Kilbourne A, Niliboff B, Mayer E A. The impact of irritable bowel syndrome on health-related quality of life.  Gastroenterology. 2000;  119 654-660
    CrossrefPubMedGoogle Scholar
  • 26 Stewart A L, Hays R D, Ware Jr J E. The MOS short-form general health survey. Reliability and validity in a patient population.  Med Care. 1988;  26 724-735
    CrossrefPubMedGoogle Scholar

James W SmithM.D. 

Department of Gastroenterology and Hepatology

Ochsner Clinic Foundation, 1514 Jefferson Hwy.

New Orleans, LA 70121

Email: Jsmith@ochsner.org

      >